Basel: Sandoz has announced the European launch of Wyost (denosumab 120 mg) and Jubbonti (denosumab 60 mg). The medicines are ...

Samsung Bioepis Co., Ltd. today announced the launch of OBODENCE™ (60 mg pre-filled syringe) and XBRYK™ (120 mg vial), ...

On November 24, 2025, Alvotech announced that the European Commission (EC) has approved AVT03 as a biosimilar to Amgen’s PROLIA® and ...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...

Accord Healthcare today announced the launch of Osvyrti (denosumab), a biosimilar to Prolia® (Amgen), and Jubereq (denosumab) ...

Samsung Bioepis launches denosumab biosimilars, Obodence and Xbryk in Europe: Incheon, Korea Tuesday, December 2, 2025, 14:00 Hrs [IST] Samsung Bioepis Co., Ltd. announced the lau ...

Samsung Bioepis Co., Ltd. today announced the launch of OBODENCEtm (60 mg pre-filled syringe) and XBRYKtm (120 mg vial), denosumab biosimilars referencing Prolia and Xgeva. The products will be ...

OBODENCE (60 mg pre-filled syringe) and XBRYK (120 mg vial) become available across Europe as of December 2025 and January 2026, respectively Marks Samsung Bioepis' 10th and 11th biosimilars ...

Dr. Reddy's Laboratories has secured European Commission marketing approval for AVT03, a biosimilar to Prolia and Xgeva, used ...

Understood. Please provide the article or its content, and I'll generate an SEO-friendly meta description as per your ...

Dr Reddys Laboratories announced that the European Commission (EC) has granted marketing authorization for AVT03, a biosimilar of Prolia (denosumab) and Xgeva (denosumab).